- Home
- BIVI vs VYNE Comparison
BIVI vs VYNE Comparison
Compare BIVI & VYNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIVI
- VYNE
- Stock Information
- Founded
- BIVI 2013
- VYNE 2003
- Country
- BIVI United States
- VYNE United States
- Employees
- BIVI N/A
- VYNE N/A
- Industry
- BIVI Biotechnology: Pharmaceutical Preparations
- VYNE Biotechnology: Pharmaceutical Preparations
- Sector
- BIVI Health Care
- VYNE Health Care
- Exchange
- BIVI Nasdaq
- VYNE Nasdaq
- Market Cap
- BIVI 18.6M
- VYNE 16.0M
- IPO Year
- BIVI N/A
- VYNE 2018
- Fundamental
- Price
- BIVI $1.02
- VYNE $1.42
- Analyst Decision
- BIVI Strong Buy
- VYNE Strong Buy
- Analyst Count
- BIVI 1
- VYNE 2
- Target Price
- BIVI $30.00
- VYNE $6.25
- AVG Volume (30 Days)
- BIVI 194.8K
- VYNE 964.9K
- Earning Date
- BIVI 05-12-2025
- VYNE 08-13-2025
- Dividend Yield
- BIVI N/A
- VYNE N/A
- EPS Growth
- BIVI N/A
- VYNE N/A
- EPS
- BIVI N/A
- VYNE N/A
- Revenue
- BIVI N/A
- VYNE $605,000.00
- Revenue This Year
- BIVI N/A
- VYNE $42.51
- Revenue Next Year
- BIVI N/A
- VYNE N/A
- P/E Ratio
- BIVI N/A
- VYNE N/A
- Revenue Growth
- BIVI N/A
- VYNE 43.03
- 52 Week Low
- BIVI $0.62
- VYNE $0.85
- 52 Week High
- BIVI $7.50
- VYNE $4.30
- Technical
- Relative Strength Index (RSI)
- BIVI 47.95
- VYNE 77.62
- Support Level
- BIVI $1.00
- VYNE $0.85
- Resistance Level
- BIVI $1.09
- VYNE $0.97
- Average True Range (ATR)
- BIVI 0.07
- VYNE 0.13
- MACD
- BIVI -0.01
- VYNE 0.08
- Stochastic Oscillator
- BIVI 19.05
- VYNE 85.56
About BIVI BioVie Inc.
BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The Company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.
About VYNE VYNE Therapeutics Inc.
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ, ZILXI, and FCD105.